The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

Early-life factors are associated with body mass index trajectories in children, with risk for obesity detectable at age 3.5 years.

Experienced weight stigma improves from pre- to post-metabolic bariatric surgery, according to a recent study.